We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Vaccine Makers Have Difficult Times Ahead, Panel Says
Vaccine Makers Have Difficult Times Ahead, Panel Says
May 7, 2010
An FDA advisory panel has voiced support for continuing use of Merck’s and GlaxoSmithKline’s (GSK) contaminated rotavirus vaccines. But
the panel said manufacturers may have a hard road ahead as advanced screening tests make vaccine production more difficult and expensive.